Verrica Pharmaceuticals Q3 Revenue Reaches $6.9 Million; Net Loss Totals $12.4 Million

Verrica Pharmaceuticals reported third-quarter 2026 revenue of $6.9 million, including record U.S. YCANTH net product revenue of $5.7 million, up 57.9% year over year. The company recorded a GAAP net loss of $12.4 million, or $0.58 per share, and a non-GAAP net loss of $10.5 million, or $0.49 per s…